Atara Biotherapeutics (ATRA) Total Current Liabilities (2013 - 2026)

Atara Biotherapeutics' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• Quarterly Total Current Liabilities fell 88.21% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 88.21% YoY) and the FY2025 annual result came in at $14.9 million, down 88.91% from the prior year.
• Total Current Liabilities was $5.6 million for Q1 2026 at Atara Biotherapeutics, down from $14.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $180.7 million in Q1 2024 and bottomed at $5.6 million in Q1 2026.
• A 5-year average of $82.5 million and a median of $74.6 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 166.21% — and 2025, when it plunged 90.18%.
• Atara Biotherapeutics' Total Current Liabilities stood at $78.9 million in 2022, then soared by 80.22% to $142.2 million in 2023, then fell by 5.38% to $134.6 million in 2024, then tumbled by 88.91% to $14.9 million in 2025, then slumped by 62.17% to $5.6 million in 2026.
• Business Quant data shows ATRA's Total Current Liabilities at $5.6 million in Q1 2026, $14.9 million in Q4 2025, and $18.1 million in Q3 2025.